Management von rheumatischen Erkrankungen in Schwangerschaft und Stillzeit

Zusammenfassung

Zielsetzung Diese Empfehlungen der AGG (Sektion maternale Erkrankungen in der Schwangerschaft) sollen bei maternalen rheumatischen Erkrankungen eine schnelle Orientierung für Beratung und Management in Schwangerschaft und Stillzeit geben.

Methoden Die gängige Literatur, Konsensus- und Positionspapiere, Leitlinien und Empfehlungen anderer Fachgesellschaften wurden durch eine Arbeitsgruppe der Sektion bewertet und nach gemeinsamer Konsensusfindung in diese Empfehlungen gefasst.

Empfehlungen Das Manuskript gibt einen orientierenden Einblick in Physiologie, Pathophysiologie und Definitionen rheumatischer Erkrankungen, die für den Gynäkologen und Geburtshelfer relevant sein können. Die Empfehlungen beziehen sich auf mütterliche, fetale und neonatologische Diagnostik bei Vorliegen maternaler rheumatischer Grunderkrankungen.

Schlüsselwörter

Rheuma - Schwangerschaft - Lupus erythemathodes - Antiphospholipid-Antikörper - Arthritis - Vaskulitis

Publikationsverlauf

Eingereicht: 10. August 2023

Angenommen nach Revision: 23. Oktober 2023

Artikel online veröffentlicht:
08. Februar 2024

• References/Literatur

• 1 Arbuckle MR, McClain MT, Rubertone MV. et al. Development of autoantibodies before the clinical onset of systemic lupus erythematosus. N Engl J Med 2003; 349: 1526-1533
• 2 Andreoli L, Bertsias GK, Agmon-Levin N. et al. EULAR recommendations for womenʼs health and the management of family planning, assisted reproduction, pregnancy and menopause in patients with systemic lupus erythematosus and/or antiphospholipid syndrome. Ann Rheum Dis 2017; 76: 476-485
• 3 Tektonidou MG, Andreoli L, Limper M. et al. EULAR recommendations for the management of antiphospholipid syndrome in adults. Ann Rheum Dis 2019; 78: 1296-1304
• 4 Götestam Skorpen C, Hoeltzenbein M, Tincani A. et al. The EULAR points to consider for use of antirheumatic drugs before pregnancy, and during pregnancy and lactation. Ann Rheum Dis 2016; 75: 795-810
• 5 Sammaritano LR, Bermas BL, Chakravarty EE. et al. 2020 American College of Rheumatology Guideline for the Management of Reproductive Health in Rheumatic and Musculoskeletal Diseases. Arthritis Rheumatol 2020; 72: 529-556
• 6 Sciascia S, Radin M, Cecchi I. et al. 16th International congress on antiphospholipid antibodies task force report on clinical manifestations of antiphospholipid syndrome. Lupus 2021; 30: 1314-1326
• 7 Gordon C, Amissah-Arthur MB, Gayed M. et al. The British Society for Rheumatology guideline for the management of systemic lupus erythematosus in adults: Executive Summary. Rheumatology (Oxford) 2018; 57: 14-18
• 8 Fischer-Betz R, Haase I. [Pregnancy with lupus erythematosus-an update]. Z Rheumatol 2020; 79: 359-366
• 9 Kwok LW, Tam LS, Zhu T. et al. Predictors of maternal and fetal outcomes in pregnancies of patients with systemic lupus erythematosus. Lupus 2011; 20: 829-836
• 10 Clowse ME, Magder LS, Petri M. The clinical utility of measuring complement and anti-dsDNA antibodies during pregnancy in patients with systemic lupus erythematosus. J Rheumatol 2011; 38: 1012-1016
• 11 Buyon JP, Kim MY, Guerra MM. et al. Predictors of Pregnancy Outcomes in Patients With Lupus: A Cohort Study. Ann Intern Med 2015; 163: 153-163
• 12 Buyon JP, Kim MY, Guerra MM. et al. Kidney Outcomes and Risk Factors for Nephritis (Flare/De Novo) in a Multiethnic Cohort of Pregnant Patients with Lupus. Clin J Am Soc Nephrol 2017; 12: 940-946
• 13 Rodrigues BC, Lacerda MI, Ramires de Jesus GR. et al. The impact of different classes of lupus nephritis on maternal and fetal outcomes: a cohort study of 147 pregnancies. Lupus 2019; 28: 492-500
• 14 Smyth A, Oliveira GH, Lahr BD. et al. A systematic review and meta-analysis of pregnancy outcomes in patients with systemic lupus erythematosus and lupus nephritis. Clin J Am Soc Nephrol 2010; 5: 2060-2068
• 15 Dong Y, Yuan F, Dai Z. et al. Preeclampsia in systemic lupus erythematosus pregnancy: a systematic review and meta-analysis. Clin Rheumatol 2020; 39: 319-325
• 16 Bandoli G, Singh N, Strouse J. et al. Mediation of Adverse Pregnancy Outcomes in Autoimmune Conditions by Pregnancy Complications: A Mediation Analysis of Autoimmune Conditions and Adverse Pregnancy Outcomes. Arthritis Care Res (Hoboken) 2020; 72: 256-264
• 17 Skorpen CG, Lydersen S, Gilboe IM. et al. Influence of disease activity and medications on offspring birth weight, pre-eclampsia and preterm birth in systemic lupus erythematosus: a population-based study. Ann Rheum Dis 2018; 77: 264-269
• 18 Koh JH, Ko HS, Kwok SK. et al. Hydroxychloroquine and pregnancy on lupus flares in Korean patients with systemic lupus erythematosus. Lupus 2015; 24: 210-217
• 19 Seo MR, Chae J, Kim YM. et al. Hydroxychloroquine treatment during pregnancy in lupus patients is associated with lower risk of preeclampsia. Lupus 2019; 28: 722-730
• 20 Clowse MEB, Eudy AM, Balevic S. et al. Hydroxychloroquine in the pregnancies of women with lupus: a meta-analysis of individual participant data. Lupus Sci Med 2022;
• 21 Leroux M, Desveaux C, Parcevaux M. et al. Impact of hydroxychloroquine on preterm delivery and intrauterine growth restriction in pregnant women with systemic lupus erythematosus: a descriptive cohort study. Lupus 2015; 24: 1384-1391
• 22 Rolnik DL, Wright D, Poon LC. et al. Aspirin versus Placebo in Pregnancies at High Risk for Preterm Preeclampsia. N Engl J Med 2017; 377: 613-622
• 23 Roberge S, Nicolaides K, Demers S. et al. The role of aspirin dose on the prevention of preeclampsia and fetal growth restriction: systematic review and meta-analysis. Am J Obstet Gynecol 2017; 216: 110-120.e6
• 24 Ayala DE, Ucieda R, Hermida RC. Chronotherapy with low-dose aspirin for prevention of complications in pregnancy. Chronobiol Int 2013; 30: 260-279
• 25 Ruiz-Irastorza G, Khamashta MA. Evaluation of systemic lupus erythematosus activity during pregnancy. Lupus 2004; 13: 679-682
• 26 Yee CS, Khamashta M, Akil M. et al. The BILAG2004-Pregnancy Index is a valid disease activity outcome measure for pregnant SLE patients. Rheumatol Adv Pract 2022; 6: rkac081
• 27 Lockshin MD, Kim M, Laskin CA. et al. Prediction of adverse pregnancy outcome by the presence of lupus anticoagulant, but not anticardiolipin antibody, in patients with antiphospholipid antibodies. Arthritis Rheum 2012; 64: 2311-2318
• 28 Miyakis S, Lockshin MD, Atsumi T. et al. International consensus statement on an update of the classification criteria for definite antiphospholipid syndrome (APS). J Thromb Haemost 2006; 4: 295-306
• 29 Garcia D, Erkan D. Diagnosis and Management of the Antiphospholipid Syndrome. N Engl J Med 2018; 378: 2010-2021
• 30 Buyon JP, Winchester RJ, Slade SG. et al. Identification of mothers at risk for congenital heart block and other neonatal lupus syndromes in their children. Comparison of enzyme-linked immunosorbent assay and immunoblot for measurement of anti-SS-A/Ro and anti-SS-B/La antibodies. Arthritis Rheum 1993; 36: 1263-1273
• 31 Jaeggi E, Laskin C, Hamilton R. et al. The importance of the level of maternal anti-Ro/SSA antibodies as a prognostic marker of the development of cardiac neonatal lupus erythematosus a prospective study of 186 antibody-exposed fetuses and infants. J Am Coll Cardiol 2010; 55: 2778-2784
• 32 Brito-Zeron P, Izmirly PM, Ramos-Casals M. et al. The clinical spectrum of autoimmune congenital heart block. Nat Rev Rheumatol 2015; 11: 301-312
• 33 Brucato A, Cimaz R, Caporali R. et al. Pregnancy outcomes in patients with autoimmune diseases and anti-Ro/SSA antibodies. Clin Rev Allergy Immunol 2011; 40: 27-41
• 34 Cuneo BF, Sonesson SE, Levasseur S. et al. Home Monitoring for Fetal Heart Rhythm During Anti-Ro Pregnancies. J Am Coll Cardiol 2018; 72: 1940-1951
• 35 Friedman DM, Kim MY, Copel JA. et al. Utility of cardiac monitoring in fetuses at risk for congenital heart block: the PR Interval and Dexamethasone Evaluation (PRIDE) prospective study. Circulation 2008; 117: 485-493
• 36 Izmirly PM, Costedoat-Chalumeau N, Pisoni CN. et al. Maternal use of hydroxychloroquine is associated with a reduced risk of recurrent anti-SSA/Ro-antibody-associated cardiac manifestations of neonatal lupus. Circulation 2012; 126: 76-82
• 37 Cimaz R, Spence DL, Hornberger L. et al. Incidence and spectrum of neonatal lupus erythematosus: a prospective study of infants born to mothers with anti-Ro autoantibodies. J Pediatr 2003; 142: 678-683
• 38 Boros CA, Spence D, Blaser S. et al. Hydrocephalus and macrocephaly: new manifestations of neonatal lupus erythematosus. Arthritis Rheum 2007; 57: 261-266
• 39 Levy R, Briggs L, Silverman E. et al. Cutaneous sequelae in neonatal lupus: A retrospective cohort study. J Am Acad Dermatol 2020; 83: 440-446
• 40 Dima A, Jurcut C, Chasset F. et al. Hydroxychloroquine in systemic lupus erythematosus: overview of current knowledge. Ther Adv Musculoskelet Dis 2022; 14
• 41 Izmirly P, Kim M, Friedman DM. et al. Hydroxychloroquine to Prevent Recurrent Congenital Heart Block in Fetuses of Anti-SSA/Ro-Positive Mothers. J Am Coll Cardiol 2020; 76: 292-302
• 42 Eudy AM, McDaniel G, Clowse MEB. Pregnancy in rheumatoid arthritis: a retrospective study. Clin Rheumatol 2018; 37: 789-794
• 43 Ruiz-Irastorza G, Lima F, Alves J. et al. Increased rate of lupus flare during pregnancy and the puerperium: a prospective study of 78 pregnancies. Br J Rheumatol 1996; 35: 133-138
• 44 Barrett JH, Brennan P, Fiddler M. et al. Does rheumatoid arthritis remit during pregnancy and relapse postpartum? Results from a nationwide study in the United Kingdom performed prospectively from late pregnancy. Arthritis Rheum 1999; 42: 1219-1227
• 45 [Anonymous] Reducing the Risk of Venous Thromboembolism during Pregnancy and the Puerperium – RCOG Green-top Guideline No. 37a. 2015. Accessed Decemver 22, 2023 at: https://www.rcog.org.uk/media/qejfhcaj/gtg-37a.pdf
• 46 Anderson JE, Held N, Wright K. Raynaudʼs phenomenon of the nipple: a treatable cause of painful breastfeeding. Pediatrics 2004; 113: e360-e364
• 47 Barrett ME, Heller MM, Stone HF. et al. Raynaud phenomenon of the nipple in breastfeeding mothers: an underdiagnosed cause of nipple pain. JAMA Dermatol 2013; 149: 300-306
• 48 Anderson PO. Drug Treatment of Raynaudʼs Phenomenon of the Nipple. Breastfeed Med 2020; 15: 686-688
• 49 Jethwa H, Lam S, Smith C. et al. Does Rheumatoid Arthritis Really Improve During Pregnancy? A Systematic Review and Metaanalysis. J Rheumatol 2019; 46: 245-250
• 50 Huang W, Wu T, Jin T. et al. Maternal and fetal outcomes in pregnant women with rheumatoid arthritis: a systematic review and meta-analysis. Clin Rheumatol 2023; 42: 855-870
• 51 Eudy AM, McDaniel G, Clowse ME. Pregnancy outcomes, fertility, and family planning in women with psoriatic arthritis. Obstet Med 2020; 13: 70-75
• 52 Giovannopoulou E, Gkasdaris G, Kapetanakis S. et al. Ankylosing Spondylitis and Pregnancy: A Literature Review. Curr Rheumatol Rev 2017; 13: 162-169
• 53 Ghalandari N, Kemper E, Crijns IH. et al. Analysing cord blood levels of TNF inhibitors to validate the EULAR points to consider for TNF inhibitor use during pregnancy. Ann Rheum Dis 2022; 81: 402-405
• 54 Romanowska-Prochnicka K, Felis-Giemza A, Olesinska M. et al. The Role of TNF-alpha and Anti-TNF-alpha Agents during Preconception, Pregnancy, and Breastfeeding. Int J Mol Sci 2021; 22: 2922
• 55 Nielsen OH, Gubatan JM, Juhl CB. et al. Biologics for Inflammatory Bowel Disease and Their Safety in Pregnancy: A Systematic Review and Meta-analysis. Clin Gastroenterol Hepatol 2022; 20: 74-87.e3
• 56 Tardif ML, Mahone M. Mixed connective tissue disease in pregnancy: A case series and systematic literature review. Obstet Med 2019; 12: 31-37
• 57 Sims C, Clowse MEB. A comprehensive guide for managing the reproductive health of patients with vasculitis. Nat Rev Rheumatol 2022; 18: 711-723